Heat Biologics reports larger loss on higher R&D expenses
Drug development company Heat Biologics reported a larger-than-expected second quarter loss due to higher research and development expenses
Read Moreheat biologics
Durham-based Heat Biologics takes in $20.7M from stock and warrants offering
Posted by WRAL News | May 8, 2018
Heat Biologics, which is developing immunotherapies to battle cancer, has sold nearly $20.7 million in a stock and warrants offering.
Read MoreHeat Biologics, Argos Therapeutics seek to bolster stock with reverse splits
Posted by WRAL TechWire | Jan 22, 2018
Heat Biologics and Argos Therapeutics are executing reverse stock splits in an attempt to drive up value for their respective shares.
Read More
